The NET G3 enigma: dealing with a “new” entity

Markus Raderer · Barbara Kiesewetter

Summary  Neuroendocrine neoplasms of the gastrointestinal system (GEP-NENs) have historically been graded into well-differentiated neuroendocrine tumors (NETs) G1 and 2 and undifferentiated neuroendocrine carcinomas (NEC) G3 according to the proliferative index Ki-67, with the latter being larger than 20% for G3 NENs. However, clinical and pathological findings have suggested G3 NENs to be heterogeneous, and the most recent World Health Organization (WHO) classification has further subdivided G3 NENs into NET G3 with differentiated features and a usually lower Ki-67 (20–55%) as opposed to undifferentiated NECs. Currently, however, no standard approach to patients with NET G3 has been defined. As opposed to NET G1/G2, application of somatostatin analogues is not recommended, and the response to platinum-based chemotherapy is inferior when compared to NEC. The objective of this short review is to summarize pathological characteristics as well as therapeutic data obtained in patients with NET G3.

Keywords  Neuroendocrine tumor grade 3 · Classification · Chemotherapy · Peptide receptor radiotherapy · Somatostatin analogues

Introduction

Neuroendocrine neoplasms (NENs) are relatively rare, but have been demonstrated to show an increasing incidence worldwide [1, 2]. According to Surveillance, Epidemiology and End Results (SEER) data, the lung is the most common site of origin, followed by the gastrointestinal (GI) tract including the pancreas and the small bowel [3]. Due to peculiar event during embryogenesis, however, neuroendocrine cells can be found scattered throughout the human body giving rise to NENs. Within the GI tract, the majority of NENs are highly differentiated tumors formerly termed carcinoids, which are graded according to the proliferative index as assessed by the Ki-67 index into “NET G1” and “NET G2”, while in the lung the term “carcinoid” is still used for G1 and “atypical carcinoid” for G2 tumors [4–6]. A prospective Austrian incidence study has assessed pathological diagnoses of GI-NETs and found an incidence of 2.56/100,000 inhabitants with the majority being found in the stomach [7].

While the features and clinical characteristics of differentiated NETs have been studied in detail in recent decades, more aggressive NENs have only more recently been given more attention. Initially graded as neuroendocrine carcinoma (NEC) if a Ki-67 of more than 20% was documented by immunohistochemistry, these malignancies have historically been treated according to small cell lung cancer. Clinical and pathological data, however, have led to a more refined grading with further distinction between NET G3 and NEC.

In this short overview, recent developments in NET G3 will be summarized and discussed.

Historical development—the Nordic NEC study

The first study to suggest a heterogeneous behavior of—what was then called—NEC/WHO G3 within the GI tract was a retrospective analysis published by Sorbye and coworkers in 2013 [8]. A total of 305 patients (301 with metastatic and 4 with locally advanced, unresectable tumors) were included, and the aggressive nature of the disease was impressively underscored
by the median overall survival (OS) of 11 months in the 252 patients undergoing chemotherapy and a median OS of 1 month in the 53 patients having only best supportive care. Additional negative prognostic factors identified were elevated LDH, thrombocytosis, impaired performance status and a colorectal origin of the disease. Further analysis, however, disclosed a difference in terms of Ki-67 index, with a cut-off of 55% being suggested to divide between two prognostically different subgroups. While the response rate to platinum-based chemotherapy was significantly lower (15% vs 42%, \( p = 0.001 \)), the overall survival was longer in patients with a Ki-67 < 55% (14 months vs 10 months, \( p = 0.001 \)).

These data were the first to suggest that platinumbased therapy might not be the optimal therapy for NEN patients with a Ki-67 between 20–55%, while it is still standard therapy for patients with NECs in analogy to pulmonary NECs.

**Current classification of NENs**

The accumulating clinical and pathological data generated after the Nordic NEC trial are reflected in most current World Health Organization (WHO) classification published in 2017 [5]. One of the major changes (in addition to increasing the Ki-67 cutoff for distinction to between NET G1 and NET G2 to 3%) was the definition of a totally new entity termed NET G3. The distinction between NET G3 and NEC is mostly based on morphology, but as already suggested by Sorbye and coworkers [8], NET G 3 is mostly characterized by a lower Ki-67 index, i.e., between 20–55%, while patients with NEC show a median Ki 67 of 80% [5, 9, 10]. Still, the presence of distinct small cell (43%) or large cell (57%) histology defines a NEC even with a lower proliferative index, while NET G3 patients with higher Ki-67 also exist. In the lung, the proliferative grading is based rather on the mitotic index (>20/HPF) than Ki-67 [6]. NET G3 was initially defined only for pancreatic NENs [5], but has now widely been accepted irrespective of the site of origin [10].

In initial studies on pancreatic NET G3, the underlying “low grade” component as opposed to NEC of the pancreas was thought to be a distinguishing feature, as was the presence of MEN1, DAXX and ATRX mutations [10–14]. Using these criteria, NET G3 of the pancreas were found to have an OS of 99 months as opposed to 17 months for NET G2 patients with higher Ki-67 also exist. In the lung, the proliferative grading is based rather on the mitotic index (>20/HPF) than Ki-67 [6]. NET G3 was initially defined only for pancreatic NENs [5], but has now widely been accepted irrespective of the site of origin [10].

In initial studies on pancreatic NET G3, the underlying “low grade” component as opposed to NEC of the pancreas was thought to be a distinguishing feature, as was the presence of MEN1, DAXX and ATRX mutations [10–14]. Using these criteria, NET G3 of the pancreas were found to have an OS of 99 months as opposed to 17 months for NET G2 patients with higher Ki-67 also exist. In the lung, the proliferative grading is based rather on the mitotic index (>20/HPF) than Ki-67 [6]. NET G3 was initially defined only for pancreatic NENs [5], but has now widely been accepted irrespective of the site of origin [10].

As compared to differentiated NETs G1 and G2, the high grade NENs (NET G3 and NEC) are still rare, with only up to 15% of NENs being high grade (9% extra-pulmonary, 3% within the GI tract).

In terms of molecular characteristics, recent studies have consecutively unraveled the differences between GI-NET G 3 and NECs. In a cohort of 136 patients with GEP-NEN G3, immunohistochemical expression of PD-L1 was assessed and found to be low with only 14 patients (10%) showing immunoreactivity (4 in the tumor cells and 10 with immunoreactive immune cells). In this series, PD-L1 positivity was exclusively found in undifferentiated NEC patients, but not in NENs as far as the presentation of the data allowed extraction of definitive histologies [15]. This underscores another problem when dealing with NET G3 that a lumping with NEC within the same analysis under the basket heading “NEN G3” is still performed without definitive distinction between NEC and NET G3. Tumor mutational burden, however, has also been reported as low for both entities (5.1 for NEC and 6.9 for NET G3), which might explain the unsuccessful attempts to implicate checkpoint inhibitors in the therapy of these patients (for review see [10, 13]). In addition, NET G3 is characterized by a lower MSI rate of around 3% [13, 14].

**Treatment of NET G3—the clinicians’ dilemma**

To date, the optimal first line therapy in patients with NET G3 has not been established, although recommendations in current guidelines have favored treatment approaches based on systemic approaches to pancreatic NETs with the exception of somatostatin analogues (SSA), which is not recommended in any guideline and should be restricted to patients with NET G1/G2 [9, 10].

Following distinction between NET G3 and NEC, however, potential surgical intervention whenever possible is now being advocated in NET G3 patients, and it has been stated that the guidelines for surgery in patients with NET G3 should be similar than for NET G2 [16, 17].

For patients not amenable to surgery, however, no formal prospective trials exist, but the ENETS, the ESMO as well the Nordic guidelines [9, 10, 18] suggest the combination of temozolomide/capcitabine or streptozotocin/5-FU, the mTOR inhibitor everolimus or sunitinib in case of a pancreatic origin as potential first-line therapies.

Limited data on the use of temozolomide-based therapies in NET G3 exist, with one of the largest retrospective analyses having been published by Rogowski and coworkers in 2019 [19]. In this series, 20 patients with NET G3 and 12 with NEC of the GI tract having been treated with temozolomide/capcitabine were analyzed. A progression-free survival (PFS) of 15.3 months with an overall survival (OS) of 22 months was found in this cohort, which was significantly better than the results obtained for NECs (PFS 3.3 and OS 4.6 months, respectively).

The use of everolimus to date is only substantiated by a retrospective analysis of 15 patients with G3 neoplasms with a Ki-67 < 55%, resulting in a median PFS of 6 months, and an OS of 28 months [20]. The authors suggested a higher benefit for patients given the...
mTOR inhibitor as first-line therapy, with 3/4 patients having a PFS of 12, 17 and 22 months, respectively.

Sunitinib at a dose of 37.5 mg daily was given to 31 patients with GEP-NEN G3, 26 of whom had tissue available for exact grading [21]. In total, the majority of patients were graded as NECs (n=20) and only 6 had NET G3, 4 of whom were rated as responders. Median PFS was 42 days and OS 181 days for the whole cohort, and at the time of analysis 2 patients with NET G3 had died, and median survival could not be calculated. In a retrospective analysis reported by Mizuno et al [22], the effect of sunitinib on 60 pancreatic NETs including 10 with NET G3 was assessed. The authors reported a 1-year PFS of 44%, 40% and 0% for NET G1/G2, NET G3 and NEC, respectively, with 4/10 NET G3 patients rated as PR and suggested a comparable efficacy for sunitinib in NET G3 to NET G1/G2.

These data, however, have to be interpreted with caution, and prospective studies are clearly needed to assess the exact impact of those therapies.

In keeping with prior data, application of cisplatin/etoposide should be reserved for patients with clinically aggressive tumors or a Ki-67 > 55% [9, 10].

While somatostatin-receptor targeting methods are not recommended as the imaging of choice and 18F-FDG-PET/CT is thought to be more sensitive in NET G3 [10, 23], detection of somatostatin receptors (SSTR2) is still an important information in patients especially with NET G3. Peptide receptor radiotherapy (PRRT) directed against SSTR2 is a highly effective and approved therapy in patients with NET G1/G2 after progression during therapy with an unlabeled SST analogue [24]. No prospective data in NET G3 exist so far, but a recently published retrospective analysis has shown promising results for both NET G3 and NEC [25]. A multicenter analysis including 149 patients with GEP-NEN G3 disclosed 1% complete response, 41% partial remission, 38% stable disease and only 20% progressed during therapy. The median PFS was 14 months with an OS of 29 months. These results are especially promising, as the majority of patients had been pretreated (62 received PRRT as second-line therapy and 57 even later). The subgroup of NET G3 had a better outcome when compared to the undifferentiated patients, with the median PFS being 19 vs 8 months and the OS 31 vs 9 months. When broken down by Ki-67 index, patients with a Ki-67 < 55% (n=125) had a longer PFS (16 months) and OS (31 months) when compared to patients with Ki-67 > 55% (PFS 6 months, OS 9 months). While no formal comparison with other forms of therapy has been performed, these results appear superior to other systemic treatments even in the first line. In view of this, assessment of SSTR status preferably by 68-Ga-DOTANOC-PET CT in patients with NET G3 seems reasonable in order select individual patients suitable for PRRT.

Conclusion

The definition of NET G3 has been inevitable since the publication of the Nordic NEC study in 2013 [8], but has left the NET-community—especially clinicians—with more questions than answers. While being apparently more indolent than NEC and less prone to responding to platinum-based therapy, little progress has been made in the therapy of those patients. To date, no standard first-line therapy has been established and the results on which recommendations laid down in the current guidelines are based appear pretty thin. The most promising and solid data, even though retrospective, appear to result from application of PRRT in patients with SSTR-positive tumors. Other than that, the frontline management of patients is dependent on the clinical aggressiveness, i.e. platinum-based therapy and the preference and experience of the respective centers in the use of either chemotherapy as used for pancreatic NET G1/G2 or targeted therapies such as everolimus and sunitinib. Various negatives, however, have been clearly defined including the absence of benefit from checkpoint inhibitors or application of unlabeled SSA. In view of this situation, multinational efforts are clearly needed in the future to advance our knowledge in this field.

Funding Open access funding provided by Medical University of Vienna.

Conflict of interest M. Raderer and B. Kiesewetter declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
2. Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:R153–R63.
3. Yao J, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
4. Perren A, Couvelard A, Scoazec JY, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology, diagnosis and prognostic stratification. Neuroendocrinology. 2017;105:196–200.
5. Kloeppel G. Pancreatic neuroendocrine neoplasias. In: The WHO classification of endocrine tumours. Lyon: IARC Press; 2017.
6. Travis WDEBAPB, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015.
7. Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic tumors: current data on a prospectively collected, retrospectively analyzed multicenter investigation. Oncologist. 2011;16(5):602–13.
8. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–60.
9. Tiensuu Janson E, Knigge U, Dram G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2021;60(7):931–41.
10. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
11. Rindi G, Klersy C, Albarello L, et al. Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study. Neuroendocrinology. 2018;107(4):375–86.
12. Heetfeld M, Chougnet CM, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64.
13. Rinke A, Auenhammer CJ, Bodei L, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalized medicine? Gut. 2021;70:1768–81.
14. Puccini A, Poormian K, Salem ME, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clin Cancer Res. 2020;26:5943–51.
15. Ali AS, Langer SW, Federspiel B, et al. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE. 2020;15(12):e243900.
16. Sorbye H, Baudin E, Òrbath R, et al. Unmet medical needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 2019;108(1):54–62.
17. Holmager P, Langer S, Kjaer A, et al. Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high-grade mixed neuroendocrine-non-neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23(6):806–17.
18. García-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.
19. Rogowski W, Wachula E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma—retrospective analysis. Endokrynol Pol. 2019;70(4):313–7.
20. Panzuto F, Rinzivillo M, Spada F, et al. Everolimus in pancreatic neuroendocrine carcinomas G3. Pancreas. 2017;46:302–5.
21. Pellat A, Dreyer C, Couffignal C, et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107:237–45.
22. Mizuno Y, Kudo A, Akashi T, et al. Sunitinib shrinks NET G3 neuroendocrine pancreatic neoplasms. J Cancer Res Clin Oncol. 2018;144(6):1155–63.
23. Binderup T, Knigge U, Loft A, et al. 18F-fluorodesoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.
24. Strosberg J, E-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumours. N Engl J Med. 2017;376:125–35.
25. Carløe EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic high-grade neuroendocrine neoplasms: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–39.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

For late news from international oncology congresses see: http://www.springermedizin.at/memo-inoncology